tiprankstipranks
Advertisement
Advertisement

CVKD Stock Latest News

Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright
The FlyCadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright
3d ago
CVKD
Cadrenal Therapeutics Inc trading halted, volatility trading pause
PremiumThe Fly
Cadrenal Therapeutics Inc trading halted, volatility trading pause
9d ago
CVKD
Cadrenal Therapeutics Inc trading resumes
PremiumThe Fly
Cadrenal Therapeutics Inc trading resumes
9d ago
CVKD
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement
PremiumCompany Announcements
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement
9d ago
8K
CVKD
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk
PremiumCompany Announcements
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk
10d ago
CVKD
Cadrenal Therapeutics, Inc. (CVKD) Q4 Earnings Cheat Sheet
PremiumPre-EarningsCadrenal Therapeutics, Inc. (CVKD) Q4 Earnings Cheat Sheet
25d ago
CVKD
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease
Premium
Company Announcements
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease
29d ago
8K
CVKD
Cadrenal Therapeutics highlights research on 12-LOX inhibition
Premium
The Fly
Cadrenal Therapeutics highlights research on 12-LOX inhibition
29d ago
CVKD
Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion
PremiumThe Fly
Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion
1M ago
CVKD
Cadrenal Highlights Mixed Phase 2 Results for CAD-1005
PremiumCompany Announcements
Cadrenal Highlights Mixed Phase 2 Results for CAD-1005
2M ago
8K
CVKD
Cadrenal Therapeutics announces Phase 2 results for CAD-1005
PremiumThe Fly
Cadrenal Therapeutics announces Phase 2 results for CAD-1005
2M ago
CVKD
Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution
PremiumThe Fly
Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution
3M ago
CVKD
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity
PremiumCompany AnnouncementsCadrenal Therapeutics Expands At-The-Market Stock Offering Capacity
4M ago
8K
CVKD
Cadrenal Therapeutics Announces New Securities Purchase Agreement
Premium
Company Announcements
Cadrenal Therapeutics Announces New Securities Purchase Agreement
4M ago
8K
CVKD
Cadrenal Therapeutics Acquires VLX-1005 from Veralox
Premium
Company Announcements
Cadrenal Therapeutics Acquires VLX-1005 from Veralox
4M ago
8K
CVKD
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia
PremiumThe Fly
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia
4M ago
CVKD
Cadrenal Therapeutics Appoints Dr. Golden to Board
PremiumCompany Announcements
Cadrenal Therapeutics Appoints Dr. Golden to Board
4M ago
8K
CVKD
Cadrenal Therapeutics appoints Lee Golden to board of directors
PremiumThe Fly
Cadrenal Therapeutics appoints Lee Golden to board of directors
4M ago
CVKD
PTCT
Cadrenal Therapeutics Announces New Stock Offering Program
PremiumCompany Announcements
Cadrenal Therapeutics Announces New Stock Offering Program
5M ago
8K
CVKD
Cadrenal Therapeutics Reports Increased Losses Amid Strategic Expansion
PremiumCompany AnnouncementsCadrenal Therapeutics Reports Increased Losses Amid Strategic Expansion
5M ago
CVKD
Cadrenal Therapeutics reports Q3 EPS ($1.31) vs ($2.18) last year
Premium
The Fly
Cadrenal Therapeutics reports Q3 EPS ($1.31) vs ($2.18) last year
5M ago
CVKD
Cadrenal Therapeutics Elects New Director at Meeting
Premium
Company Announcements
Cadrenal Therapeutics Elects New Director at Meeting
7M ago
8K
CVKD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >